TICKERNERD
Menu
LGVNLGVNHealthcare · Biotechnology

LGVN Stock Forecast: Longeveron, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$2.37

The 2 Wall Street analysts covering Longeveron, Inc. hold a median 12-month price target of $61 — +2484.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 28 of 100 as at 8 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$7.8M
Ticker Nerd rank
28 / 100
Median analyst target
$61
Analysts covering
2
Revenue$287K−9.2% y/y
Operating income−$6.2M
Net income−$6.1M
Free cash flow−$5.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

LGVN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Longeveron, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
28 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
93
Accruals
84
Volatility
49
Issuance
46
Quality
37
Revisions
31
Growth
28
Momentum
15
Value
5

Size (93): Smaller than most of the companies we track.

Value (5): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

LGVN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LGVN, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says2 analysts
1 Buy1 Hold0 Sell
Low $43Median $61High $80

The green dot is the last close — the median target sits +2484.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
11 May 2026Maxim GroupDowngradeHold—
4 May 2026HC Wainwright & Co.MaintainsBuy$10 → $8.00
15 Aug 2025Roth CapitalMaintainsBuy—
21 Mar 2025HC Wainwright & Co.ReiteratesBuy—
3 Mar 2025HC Wainwright & Co.ReiteratesBuy—
5 Dec 2024Roth MKMInitiatesBuy—
25 Nov 2024HC Wainwright & Co.ReiteratesBuy—
4 Nov 2024HC Wainwright & Co.ReiteratesBuy—
4 Sept 2024HC Wainwright & Co.ReiteratesBuy—
27 Aug 2024Maxim GroupMaintainsBuy—
15 Aug 2024HC Wainwright & Co.ReiteratesBuy—
31 July 2024HC Wainwright & Co.ReiteratesBuy—
29 July 2024HC Wainwright & Co.MaintainsBuy—
17 May 2024HC Wainwright & Co.ReiteratesBuy—
29 Apr 2024HC Wainwright & Co.MaintainsBuy—
4 Dec 2023HC Wainwright & Co.InitiatesBuy—
1 June 2023EF HuttonAssumesBuy$13
16 May 2023EF HuttonReiteratesBuy—
9 May 2023EF HuttonReiteratesBuy—
27 Mar 2023EF HuttonReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LGVN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

LGVN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

Longeveron, Inc. (LGVN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
2.9×

Cheaper than 68% of US stocks

Price / sales
6.6×

Cheaper than 19% of US stocks

Price / book
0.7×

Cheaper than 79% of US stocks

EV / EBITDA
0.1×

Cheaper than 61% of US stocks

Growth & margins
Revenue growth (YoY)
−9.2%

Higher than 16% of US stocks

Earnings growth (YoY)
−9.2%

Higher than 27% of US stocks

Gross margin
63.4%

Higher than 77% of US stocks

Operating margin
−2150.2%

Higher than 4% of US stocks

Net margin
67.0%

Higher than 98% of US stocks

Returns & dividend
Return on equity
−203.6%

Higher than 7% of US stocks

Return on assets
−90.9%

Higher than 3% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Longeveron, Inc. (LGVN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Longeveron, Inc. has a market value of $7.8M and an enterprise value of −$1.7M.

  • Revenue in the twelve months to 30 June 2026: $1.2M. The latest quarter shrank 9.2% year on year.

  • Net income over the same four quarters: −$23.5M, a −1977.6% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$20.7M.

  • Shares outstanding: 31.7M.

  • Trailing P/E: 2.9×; forward P/E: −1.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Longeveron, Inc. employs 38 people — $31K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

LGVN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
LGVNLongeveron, Inc.$7.8M
28
SNGXSoligenix, Inc.$7.5M
27
CLGNCollPlant Biotechnologies Ltd.$7.5M
26
CURXCuranex Pharmaceuticals, Inc.$7.5M
6
SKYESkye Bioscience, Inc.$7.4M
36
FBLGFibroBiologics, Inc.$7.4M
42
CNSPCNS Pharmaceuticals, Inc.$7.8M
23

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Longeveron, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LGVN news & analysis

Longeveron to Participate in Three Longevity/Aging Investment Conferences

GlobeNewsWire · 30 Sept 2026neutral

Longeveron Inc., a clinical-stage regenerative medicine biotechnology company developing cellular therapies for aging-related conditions, announced it will participate in three upcoming Longevity/Aging investment conferences. The announcement was made via GlobeNewsWire on September 30, 2026.

Why it matters — Participation in these specialized investment conferences could raise the company's visibility among investors focused on the longevity and aging sector, a core area of Longeveron's work.

Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)

GlobeNewsWire · 16 Sept 2026negative

Longeveron reported topline results from its ELPIS II Phase 2b trial of laromestrocel in 40 infants with hypoplastic left heart syndrome, indicating the trial did not meet its primary endpoint of improvement in right ventricular ejection fraction at month 12. The company is analyzing exploratory endpoints, plans to discuss a path forward with the FDA, and is exploring all options to maximize shareholder value.

Why it matters — The missed primary endpoint in a key Phase 2b trial represents a setback for laromestrocel's HLHS program and prompts the company to reevaluate its strategy and pursue cost-containment measures.

Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewsWire · 3 Sept 2026neutral

Longeveron announced it will present at the H.C. Wainwright 28th Annual Global Investment Conference, held September 14-16, 2026. The company's presentation is scheduled for September 14, 2026 at 1:00pm ET.

Why it matters — This gives LGVN watchers an opportunity to hear the company's latest updates at a notable investment conference.

Longeveron Announces 1-for-10 Reverse Stock Split

GlobeNewsWire · 24 Aug 2026neutral

Longeveron announced a 1-for-10 reverse split of its Class A and Class B common stock. The split was previously approved by stockholders at the company's annual meeting on July 1, 2026, and by the Board of Directors on July 31, 2026.

Why it matters — A reverse stock split changes the share structure and per-share price of LGVN stock, which shareholders and watchers would want to track.

FAQ

Frequently asked questions about LGVN stock

What is the LGVN stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Longeveron, Inc. have a median 12-month price target of $61, with estimates ranging from $43 to $80. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LGVN stock a buy right now?

Of the 2 analysts covering Longeveron, Inc., 1 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Longeveron, Inc. 28 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LGVN?

As at 8 Oct 2026, Longeveron, Inc. ranks 28 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (93 of 100).

Will LGVN stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +2484.4% from the last close, and Ticker Nerd's factor model ranks Longeveron, Inc. 28 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LGVN stock forecast for 2030?

No analyst covering Longeveron, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LGVN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $43 to $80 over the next 12 months.

What does Longeveron, Inc. do?

Longeveron Inc. Class A Common Stock represents ownership in Longeveron Inc., a clinical-stage biotechnology company focused on regenerative medicine and cellular therapies.

What is the latest news on LGVN?

The most recent item we track (GlobeNewsWire, 30 Sept 2026): "Longeveron to Participate in Three Longevity/Aging Investment Conferences". Longeveron Inc., a clinical-stage regenerative medicine biotechnology company developing cellular therapies for aging-related conditions, announced it will participate in three upcoming Longevity/Aging investment conferences. The announcement was made via GlobeNewsWire on September 30, 2026.

Company

About Longeveron, Inc.

Longeveron Inc. Class A Common Stock represents ownership in Longeveron Inc., a clinical-stage biotechnology company focused on regenerative medicine and cellular therapies. The company develops allogeneic medicinal signaling cell-based products designed to address serious pediatric, aging-related, and other life-threatening conditions. Its current programs center on Lomecel-B, a lead investigational therapy being studied across several clinical indications, including hypoplastic left heart syndrome, Alzheimer’s disease, pediatric dilated cardiomyopathy, and aging-related frailty. Longeveron’s work spans cell therapy research, clinical development, and translational medicine, placing it within the broader biotechnology sector. Headquartered in Miami, Florida, Longeveron serves as a specialized player in the market for advanced biological treatments aimed at unmet medical needs.

CEO Mr. Stephen H. Willard Esq. · 38 employees · United States · https://longeveron.com